This study is in progress, not accepting new patients
Matched Targeted Therapy For High-Risk Leukemias and MDS
Summary
- Eligibility
- for people ages up to 30 years (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Elliot Stieglitz
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Elliot Stieglitz
Juvenile myelomonocytic leukemia (JMML) is a blood cancer that affects young children and is often difficult to diagnose and treat. Currently available therapies cure only half of patients, with some children experiencing an aggressive disease course while a rare group get better with very little treatment. We have now shown that presence of secondary mutations at diagnosis pr…
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Dana-Farber Cancer Institute
- ID
- NCT02670525
- Study Type
- Interventional
- Participants
- At least 338 people participating
- Last Updated